AUTHORS
Maria J. Fernandez-Turizo, MD, Parastoo B. Dahi, MD2, Michael Scordo, MD3, David Nemirovsky, MS4, Sarah Samorodnitsky, PhD5, Mohammad Alhomoud, MD6, Moneeza Walji, MD7, Paola Ghione, MD, MS8, Alison Moskowitz, MD9, Zachary Epstein-Peterson, MD10, Robert Stuver, MD11, Miguel-Angel Perales, MD12, Jasmine Zain, M.D.13, Steven Horwitz, M.D.14, Craig Sauter, MD15, Gunjan L. Shah, MD, MS16
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
ABSTRACT
Background: Allogeneic hematopoietic cell transplantation (allo-HCT) can provide durable disease control in mature T-cell lymphomas (TCL), where graft-versus-lymphoma (GVL) activity is central to long-term remission. Post-transplant cyclophosphamide (PTCy) is standard graft-versus-host disease (GVHD) prophylaxis across donor sources for reduced intensity/non-myeloablative (RIC/NMA) conditioned allo-HCT. However, evidence derives largely from patients with myeloid malignancies. Because PTCy depletes alloreactive donor T cells early after allo-HCT, it may attenuate GVL in TCL. Prior studies have focused on donor source rather than GVHD prophylaxis, with no direct comparison of PTCy vs non-PTCy regimens in TCL. We compared relapse, overall survival (OS), progression-free survival (PFS), and non-relapse mortality (NRM) between PTCy- and non-PTCy-based prophylaxis.
Methods: We retrospectively studied adults undergoing allo-HCT for mature TCL at Memorial Sloan Kettering Cancer Center from January 2010 to March 2026. Analysis was restricted to RIC/NMA conditioning. Patients were grouped by PTCy- vs non-PTCy prophylaxis; the most common non-PTCy regimen was tacrolimus/methotrexate (n=73, 78%). Relapse and NRM were analyzed as competing events using cumulative incidence functions and Gray's test, with Fine-Gray subdistribution hazard models for associated factors. OS and PFS from time of allo-HCT were estimated by Kaplan-Meier and compared by log-rank. Multivariable models were adjusted for age, sex, disease status at transplant, and donor matching. Relapse by prophylaxis was examined within the largest histologic subtypes as an exploratory analysis.
Results: We analyzed 162 RIC/NMA-conditioned patients (69 PTCy, 93 non-PTCy). Median age was 58 years; most common subtypes were nodal T-follicular helper cell lymphomas (nTFHL; n=47), comprising angioimmunoblastic type (nTFHL-AI, n=39) and NOS type (nTFHL-NOS, n=8), adult T-cell leukemia/lymphoma (ATLL, n=32), and cutaneous T-cell lymphoma (CTCL, n=30). Groups differed at baseline: PTCy recipients were transplanted more recently (median 2024 vs 2017), more often received alternative (haploidentical/mismatched-unrelated) donor allografts (71% vs 27%), and were more often in complete remission (CR) at allo-HCT (80% vs 67%). Median follow-up was shorter with PTCy (25 vs 80 months).
The 24-month cumulative incidence of relapse was higher with PTCy than non-PTCy prophylaxis (38% vs 23%; Gray's p=0.034), which remained significant after adjustment for age, sex, disease status, and donor matching (HR 2.65, 95% CI 1.39-5.06; p=0.003). Among 48 relapses, median time to relapse was 3.7 months, with 35 (72%) occurring within 6 months (6-month cumulative incidence, 32% with PTCy vs 16% without). Among the three largest subtypes, the 24-month cumulative incidence of relapse was significantly higher with PTCy in nTFHL (33% vs 7%; p=0.028), with no significant difference in ATLL (54% vs 33%; p=0.4) or CTCL (42% vs 50%; p=0.7).
NRM did not differ (24-month NRM 16% vs 16%, p=0.8). OS and PFS were numerically lower with PTCy but not statistically significant (24-month OS 57% vs 69%, adjusted HR 1.41, 95% CI 0.76-2.62; 24-month PFS 46% vs 61%, adjusted HR 1.57, 95% CI 0.90-2.73). PTCy delayed neutrophil (median 16 vs 12 days, p<0.001) and platelet (26 vs 19 days, p=0.002) engraftment. Acute GVHD did not differ between groups (day-100 grade 3+ 18% vs 12%, p=0.3). Shorter follow-up limited chronic GVHD (cGVHD) evaluation; any-grade cGVHD was numerically lower with PTCy at 12 (17% vs 26%) and 24 months (20% vs 28%; p=0.4).
Conclusions: To our knowledge, this is the largest single-center TCL cohort comparing GVHD prophylaxis platforms. Among patients with mature TCL undergoing RIC/NMA allo-HCT, PTCy appeared to be associated with higher relapse after adjustment for age, sex, disease status, and donor matching. Despite more recent transplantation and higher CR rates at allo-HCT, relapse remained higher with PTCy, particularly in nTFHL. OS and PFS were numerically lower with PTCy but not statistically significant, while NRM was comparable. Any-grade cGVHD was numerically lower with PTCy, not reaching statistical significance. PTCy remains a cornerstone of GVHD prevention in mismatched grafts and is now standard across donor sources. The observed early relapses suggest a need to evaluate novel PTCy-based approaches or alternative GVHD prophylaxis in mature TCL. Multicenter prospective studies are warranted.
DISCLOSURES
Maria J. Fernandez-Turizo, MD: No relevant conflicts of interest to declare.